Frequency of Methyletetrahydrofolate Reductase Enzyme Mutation among Sudanese Patients with Sickle Cell Anemia in Khartoum State

Nora Nahal Bouderba Bouderba; Khalid Mohamed Khalid  Elhussain; lena Hamed Alneel  Mansour; Nariman Saliman  Abdel Alazeez; Rana Kamal  Yagoub; Sumiah Abdel monim  Mohamed; Mohammed Elfatih Hussein  Ournasseir; AbdulAzeem AbdulSalam Ibrahim  Alkhidir

doi:10.52981/smlj.v8i1.2557

Nora Nahal Bouderba Bouderba Faulty of sciences of Nature and life, biology Department, university of Bechar, Algeria.
Khalid Mohamed Khalid Elhussain Department of Hematology and Immunohematology , Omdurman Islamic university -Sudan.
lena Hamed Alneel Mansour Department of Hematology and Immunohematology , Omdurman Islamic university -Sudan.
Nariman Saliman Abdel Alazeez Department of Hematology and Immunohematology , Omdurman Islamic university -Sudan.
Rana Kamal Yagoub Department of Hematology and Immunohematology , Omdurman Islamic university -Sudan
Sumiah Abdel monim Mohamed Department of Hematology and Immunohematology , Omdurman Islamic university -Sudan
Mohammed Elfatih Hussein Ournasseir Faculty of Medical Laboratory Science Omdurman Islamic university -Sudan-Omdurman Ahlia University, Faulty of Medicine- Sudan.
AbdulAzeem AbdulSalam Ibrahim Alkhidir https://orcid.org/0000-0003-3462-0999

DOI: https://doi.org/10.52981/smlj.v8i1.2557

الملخص

Background: Sickle cell disease is an autosomal recessive and chronic hemolytic anemia whose clinical manifestations arise from the tendency of the hemoglobin (HbS or sickle hemoglobin) to polymerize and deform red blood cells into the characteristic sickle shape. The homozygous state (HbSS or sickle cell anemia) is the most common form of sickle cell disease,

Methylenetetrahydrofolate reductase (MTHFR) has a major impact on the regulation of the folic acid pathway due to the conversion of 5, 10-methylenetetrahydrofolate (methylene-THF) to 5-methyl-THF. Objective: This study aimed to determine the frequency of the mutation of MTHFR in patients with sickle cell anaemia and to measure the prevalence of MTHFR mutation among the study population.

Methods: A total of 125 patients less than 17 years with sickle cell anaemia were examined for the mutation in the (MTHFR) gene.In this study we used Chelex method to extract of DNA and used Gel Electrophoresis to explain the band of homozygous or heterozygous mutation in MTHFR in locus A1298C.

Result: This study found that the frequency of mutation in MTHFR in A1298C was 19% in SCD patient (homozygous was 11.4%, while heterozygous was 7.6 %). significant relationship between mutation in MTHFR and SCD patient (P=001).

Conclusion: This study revealed that the three is high frequency of mutation of MTHFR enzyme among Sudanese patients with SCA (19%), 11.85% had heterozygous allele and 7.8% had homozygous allele.

المراجع

1. Aluoch JR. Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya. Trop Med Int Health 1997;2:568–71. an inter-action with folate status. Proc Natl Acad Sci USA 2002,99:5606-5611.
2. Kark JA, Posey DM, Schumacher HR, et al. Sickle-cell trait as a risk factor for sudden death in physical training. N Engl J Med 1987; 317:781.
3. Boccia S, Hung R, Ricciardi G, et al. Meta- and pooled analyses of the methylene tetra hydro -folate reductase C677T and A1298C poly morphis -ms and gastric cancer risk: A Huge-GSEC review. Am J Epidemiol. 2008;167: 505–516.
4. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172.
5. Ponçon N, Toty C, L'Ambert G, et al. (2007). "Biology and dynamics of potential malaria vectors in Southern France". Malar. J. 618. doi: 10.1186/1475-2875-6-18. PMC 1808464.
6. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R."Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification". Nat. Genet. 7 (2): 195–200.
7. Robien K, Ulrich CM: 5,10-Methylene tetra-hydro folate reductasepolymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003, 157:571-582.
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP et al. (May 1995). "A candidate genetic risk factor for vascular disease: a common mutation in methylene-tetrahydrofolate reductase". Nat. Genet. 10 (1): 111–3. doi: 10.1038/ng0595-111. PMID 7647779.
9. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methylenetetra-hydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998, 64:169-172.
10. Födinger M, Hörl WH, Sunder-Plassmann G (2000). "Molecular biology of 5, 10-methylenetetra- hydrofolate reductase.”. J Nephrol 13 (1): 20–33. Födinger M, Hörl WH, Sunder-Plassmann G (2000) "Molecular biology of 5, 10-methylenetetrahydro- folate reductase.". J Nephrol 13 (1): 20–33.
11. Sibani S, Christensen B, O'Ferrall E, Saadi I, Hiou-Tim F, Rosenblatt DS, Rozen R (2000). "Characterization of six novel mutations in the methylenetetra-hydrofolate reductase (MTHFR) gene in patients with homocystinuria". Hum. Mutat. 15 (3): 280–7.
12. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reduct-ase. Nat Genet. 1995;10:111–113.
13. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R (January 1996). "Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrat- ions". Circulation 93 (1): 7–9. PMID 8616944.
14. Yamada K, Chen Z, Rozen R, Matthews RG (December 2001). "Effects of common polymo- rphisms on the properties of recombinant human methylenetetrahydrofolate reductase".Proc. Natl. Acad. Sci. U.S.A. 98 (26): 14853–8. doi : 10. 1073/pnas.261469998.
15. Schwahn B, Rozen R (2001). "Polymorphisms in the methylene-tetrahydrofolate reductase gene: clinical consequences". Am J Pharma-cogenomics 1 (3): 189–201. doi:10.2165/00129785-200101030 -00004. PMID 12083967.
16. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G' (October 1999). "Polymorphisms in the methylene-tetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults". Proc. Natl. Acad. Sci. U.S.A. 96 (22): 12810–5. doi:10.1073/pnas.96.22.12810. PMC 23109. PMID 10536004.
17. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R (15 March 1997). "Methylen-etetrahydrofolate reduct ase polymorphism, dietary inter-actions, and risk of colorectal cancer". Cancer Res. 57 (6): 1098–102. PMID 9067278.
18. Abdullah Kutlar, Ferdane Kutlar, Ibrahim Turker and Canan Tural. The methylene tetrahydrofolate Reductase (C677t) Mutation as A Potential Risk Factor for Avascular Necrosis in Sickle Cell Disease Hemoglobin 2001, Vol. 25, No. 2 , Pages 213-217.
19. Yamada K, Strahler JR, Andrews PC, Matthews RG (July 2005). "Regulation of human methylenetetra-hydrofolate reductase by phos-phorylation". Proc. Natl. Acad. Sci. U.S.A. 102 (30): 10454–9.